The largest database of trusted experimental protocols

13 protocols using polyplus

1

Transfecting Human NKCC1 in HEK293T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
The human NKCC1 clone (pcDNA3.1) was provided by Dr. Shmuel Muallem at the National Institutes of Health at Bethesda, MD, United States. Plasmid DNAs were incubated in 200 μl of Jet prime buffer (Polyplus, Graffenstaden, France, #B200225) and mixed with 4 μl of the transfection reagent (Polyplus; #21Y0910L1) for 10 min. DNAs were then transferred into HEK293Tcell plates containing culture medium, and all procedures were performed according to the manufacturer’s protocol (Polyplus).
+ Open protocol
+ Expand
2

Regulation of FOXC1 by miR-149

Check if the same lab product or an alternative is used in the 5 most similar protocols
The sequence of pre-miR-149 was obtained from the miRbase database, and the binding sequences of FOXC1 and miR-149 were obtained from TargetScan. The miR-149 expression vector was constructed using synthetic oligonucleotides and cloned into the pcDNATM6.2-GW/EmGFP vector between the EcoRI and HindIII sites. The 3′-UTR of FOXC1 was synthesized and cloned into the pmiR-GLO vector between the SacI and XhoI sites. Small interfering RNAs (siRNAs) targeting FOXC1 and NC were purchased from GenePharma Biotech (Shanghai, China). The sequences are presented in Table 1. Vector or siRNA transfection was performed according to standard protocols using PolyPlus (PolyPlus, Illkirch-Graffenstaden, France).
+ Open protocol
+ Expand
3

Knockdown of vtRNA1-1 in Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
A constitutive vtRNA1-1 knockdown cell line was constructed analogous to the described MVP knockdown cell lines (see above). The target sequence on vtRNA1-1 was the following: 5′-GGCUGGCUUUAGCUCAGCG-3′. The whole shDNA sequence for the vtRNA1-1 knockdown is listed in Supplementary Table 2.
To reduce endogenous vtRNA1-1 levels in HeLa cells or HS578T cells, chemically modified chimeric ASOs were used. Therefore 5 × 106 HeLa cells were transiently transfected (jetPEI, Polyplus) with 1 μM ASOs (Exiqon), directed against vtRNA1-1 or as a control against vtRNA1-2. After 24 h, cells were collected by centrifugation (450g, 5 min), stained with Annexin V and analysed by flow cytometry (as described above). ASOs were designed as RNA/DNA/RNA chimeric oligonucleotides with a phosphorothioate backbone. Ten central deoxyribonucleotides are flanked by five 2′-O-methyl modified ribonucleotides on both sides (Supplementary Table 2).
+ Open protocol
+ Expand
4

Virus Transfection in 12-well Plates

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were seeded in 12-well plates (1 × 105 cells/well). Then, cells were transfected with the virus using Polyplus (Polyplus, NY, United States) according to the manufacturer’s instructions.
+ Open protocol
+ Expand
5

Immunomodulation of Melanoma Progression

Check if the same lab product or an alternative is used in the 5 most similar protocols
WT and miR-146a-/- mice received 200μl intraperitoneal (i.p.) injections of Isotype control antibody (200μg/mouse /treatment) (Rat IgG1, κ; Biolegend, cat#400427) or IFN-γ blocking antibody (200μg/mouse/treatment) (R4.6A2, Biolegend, cat#505707) on day 0, 4, 8, and 12.
For translational in vivo experiments, WT mice injected with melanoma in the tail vein on day 0, received anti-PD-1 antibody, i.p. on days 1, 4 8, 16, and 22. Control mice were treated in parallel with an Armenian hamster isotype control purchased from BioXcell, (cat# BE0091). Oligonucleotides inhibiting miRNA-146a (ThermoFisher mirVana™ miRNA Inhibitor, Cat#: 4464088 ID: MH10722) or scramble controls (ThermoFisher mirVana™ miRNA Inhibitor, Negative Control #1, Cat#: 4464079) were administered via tail vein injections on days 5 and 9. In vivo-jetPEI® (Polyplus, cat# 201-50G), facilitated in vivo delivery of oligonucleotides across cell membranes, for 60μg of oligonucleotides injected in 200μl volume of 5% Glucose/in vivo-jet-PEI, per product protocol.
+ Open protocol
+ Expand
6

Pseudovirus Production for HIV/Ebola Research

Check if the same lab product or an alternative is used in the 5 most similar protocols
HIV bearing Ebola virus and VSV GPs were generated by liposome-mediated transfection system (Polyplus; 25Y1801N5) as follows. 293T cells were seeded into 6-well plates at 7 × 105 cells per well and transfected with a total of 2 μg plasmid DNA when cells yielded a density of 60 to 80% confluence. Amounts of 0.4 μg GP or VSV-G and 1.6 μg pSG3.Δenv.cmvFluc were utilized according to the optimized results. The cell supernatants were harvested 48 h after transfection, centrifuged at 3,000 rpm for 10 min, filtered through a 0.45-μm-pore filter, and frozen in aliquots at −80°C. Titers of the pseudovirus were determined by an HIV p24 ELISA kit (Key-Bio, K12P2401).
+ Open protocol
+ Expand
7

OSCC Cell Line Genetic Manipulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human OSCC cell lines (CAL-27 and UM-SCC-1) were used in this research, and the source and culture conditions were the same as in previous study [5 (link)]. Polyplus (Polyplus-transfection, France) was utilized to transfect Negative Control (NC), SMYD3 siRNAs (RiboBio, Guangzhou, China) and HMGA2 siRNAs (RiboBio, Guangzhou, China) into OSCC cells according to the manufacturer’s protocol, and cells were collected after 48–72 h transfection. The virus (containing short hairpin SMYD3 (shSMYD3) or shNC, Genechem, Shanghai, China) were transduced into OSCC cells with a multiplicity of infection of 100, as recommended. Roche Transfection Reagent (Roche, Switzerland) was utilized for the transfection of SMYD3, histone methyltransferase-inactive mutant-SMYD3 (EEL) [15 (link)], and HMGA2 plasmids (Weizhenbio, Jinan, China) according to the provided protocol, and cells were collected after 48 h transfection. The procedures of RNA extraction and qRT-PCR were as shown before [2 (link)]. The sequences of siRNA/shRNA and the primers used in this experiment are listed in Additional file 2: Table S6.
+ Open protocol
+ Expand
8

Nucleolin Depletion Modulates Inflammation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Ncl depletion in mouse lung- or liver-resident cells was mediated by siRNA against NCL with in vivo-jetpei (Polyplus) or Invivofectamine 3.0 (Invitrogen), respectively. According to the manufacturer’s instructions, the siRNA-in vivo-jetpei complex (120 μg siRNA) was injected twice or siRNA-Invivofectamine complex (50 μg siRNA) was injected intravenously into the tail veins of 4-week-old C57BL/6N mice. Two days later, LPS (300 μg kg−1) was intravenously injected to the tail veins of mice for 10 h, and then the level of inflammatory RNAs, proteins, or Ncl knockdown was evaluated by qPCR or ELISA. We monitored control or lung-specific Ncl-depleted mice survival every 4 h for 2 days after intravenous administration of PBS or LPS (6 mg kg−1).
+ Open protocol
+ Expand
9

Production of SARS-CoV-2 Spike Pseudotyped Lentivirus

Check if the same lab product or an alternative is used in the 5 most similar protocols
SARS-CoV-2 Spike pseudotyped lentivirus was produced as previously described (Crawford et al., 2020 (link)). Briefly, HEK293T cells were transfected with 1 μg pHAGE-CMV-Luc2-IRES-ZsGreen-W (BEI), a lentiviral backbone plasmid expressing luciferase under a CMV promoter and an IRES followed by ZsGreen, 0.22 μg HDM-Hgpm2 (BEI), a lentiviral helper plasmid expressing HIV Gag-Pol under a CMV promoter, 0.22 μg HDM-tat1b (BEI), a lentiviral helper plasmid expressing HIV Tat under a CMV promoter, 0.22 μg pRC-CMV-Rev1b (BEI), a lentiviral helper plasmid expressing HIV Rev under a CMV promoter, and 0.34 μg of the plasmid encoding HDM-SARS2-Spike-delta21 using polyethylenimine (Polyplus) in serum-free Dulbecco’s Modified Eagle’s Medium (Sigma-Aldrich) supplemented with 25 mM HEPES buffer (Corning). Media was changed to D10 24h post-transfection. After 48h, pseudotyped lentivirus was harvested by filtering supernatant through a 0.45 μm low protein binding durapore membrane (Millipore). Frozen aliquots were stored at −80°C and viral concentrations were quantified using the colorimetric Reverse Transcriptase Assay (Sigma-Aldrich). All packaging plasmids were propagated in DH5α cells (NEB).
+ Open protocol
+ Expand
10

Pseudovirus Production for HIV/Ebola Research

Check if the same lab product or an alternative is used in the 5 most similar protocols
HIV bearing Ebola virus and VSV GPs were generated by liposome-mediated transfection system (Polyplus; 25Y1801N5) as follows. 293T cells were seeded into 6-well plates at 7 × 105 cells per well and transfected with a total of 2 μg plasmid DNA when cells yielded a density of 60 to 80% confluence. Amounts of 0.4 μg GP or VSV-G and 1.6 μg pSG3.Δenv.cmvFluc were utilized according to the optimized results. The cell supernatants were harvested 48 h after transfection, centrifuged at 3,000 rpm for 10 min, filtered through a 0.45-μm-pore filter, and frozen in aliquots at −80°C. Titers of the pseudovirus were determined by an HIV p24 ELISA kit (Key-Bio, K12P2401).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!